|
Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS)
SummaryAMR is an important public health issue worldwide. It also presents a serious economic challenge. It has been estimated that resistance at least doubles the cost of treating a bacterial infection. Antimicrobial resistance in human medicine is primarily associated with the use of antimicrobials to treat human infections. There are several risk factors which may lead to a resistance problem in humans, for example:
International public health authorities are urging countries to implement integrated AMR surveillance systems. These systems are needed to:
In 1997, Health Canada and the Canadian Infectious Disease Society convened a national consensus conference: "Controlling Antimicrobial Resistance: An Integrated Action Plan for Canadians." One of the recommendations was to establish a national surveillance system to monitor AMR in the agri-food and agriculture sectors and the impact of resistance on human health. In 2002, the Canadian Integrated Program for Antimicrobial Resistance Surveillance (CIPARS) was initiated to monitor trends in antimicrobial use and the development of resistance in selected bacterial organisms from human, animal and food sources across Canada. The program was developed to test the feasibility of a representative and methodologically unified surveillance system. CIPARS provides antimicrobial resistance and use monitoring data to assess the impact on human health. These data are crucial for making decisions for the formulation of intervention strategies to contain the spread of antimicrobial resistance. The 2002 CIPARS Report offers the most current, valid and national data available on antimicrobial resistance in the food chain. Future CIPARS surveillance data will be more comprehensive, enabling in-depth analysis of trends and correlations between antimicrobial use and resistance in livestock, food and human populations. To better understand this complex issue, parallel targeted studies are underway to clarify risk factors for the development and spread of AMR. FAQsComing soon 2002 Surveillance ReportTable of Contents
|
Last Updated: 2005-03-01 |